Donepezil Impairs Memory in Healthy Older Subjects: Behavioural, EEG and Simultaneous EEG/fMRI Biomarkers

Abstract

Rising life expectancies coupled with an increasing awareness of age-related cognitive decline have led to the unwarranted use of psychopharmaceuticals, including acetylcholinesterase inhibitors (AChEIs), by significant numbers of healthy older individuals. This trend has developed despite very limited data regarding the effectiveness of such drugs on non-clinical groups and recent work indicates that AChEIs can have negative cognitive effects in healthy populations. For the first time, we use a combination of EEG and simultaneous EEG/fMRI to examine the effects of a commonly prescribed AChEI (donepezil) on cognition in healthy older participants. The short- and long-term impact of donepezil was assessed using two double-blind, placebo-controlled trials. In both cases, we utilised cognitive (paired associates learning (CPAL)) and electrophysiological measures (resting EEG power) that have demonstrated high-sensitivity to age-related cognitive decline. Experiment 1 tested the effects of 5 mg/per day dosage on cognitive and EEG markers at 6-hour, 2-week and 4-week follow-ups. In experiment 2, the same markers were further scrutinised using simultaneous EEG/fMRI after a single 5 mg dose. Experiment 1 found significant negative effects of donepezil on CPAL and resting Alpha and Beta band power. Experiment 2 replicated these results and found additional drug-related increases in the Delta band. EEG/fMRI analyses revealed that these oscillatory differences were associated with activity differences in the left hippocampus (Delta), right frontal-parietal network (Alpha), and default-mode network (Beta). We demonstrate the utility of simple cognitive and EEG measures in evaluating drug responses after acute and chronic donepezil administration. The presentation of previously established markers of age-related cognitive decline indicates that AChEIs can impair cognitive function in healthy older individuals. To our knowledge this is the first study to identify the precise neuroanatomical origins of EEG drug markers using simultaneous EEG/fMRI. The results of this study may be useful for evaluating novel drugs for cognitive enhancement.

Functional Connectivity and Temporal Variability of Brain Connections in Adults with Attention Deficit/Hyperactivity Disorder and Bipolar Disorder

“…Consistently, we found abnormal connectivity measures in the delta band in both BD and ADHD. Nevertheless, other bands such as beta [48] should also be assessed in future studies of the DMN in BD and ADHD. …”

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

“…Another potential approach to be used within a PM paradigm is to measure the effects of a single dose [279–282] and investigate the predictive power of the single dose over the effectiveness of the therapeutic strategy for the biomarkers-characterized patient. The single dose approach has the potential to inform the tailoring of the therapeutic intervention by providing information about potential medium to long term effects of any treatment.…”

Declarative Memory

“…Three of these were in elderly subjects, one of these concerned subjects with Mild Cognitive Impairment. Three studies reported improved episodic memory performance (Gron et al 2006(Gron et al , 2005Stough et al 2009), whereas one reported impaired episodic memory performance (Balsters et al 2011). The latter was in healthy elderly subjects and the only clear factor in which this study was different than the other three reporting positive effects of cholinesterase inhibitors was that Balsters et al were using PAL, a nonverbal episodic memory task, whereas the other studies were using Word List tests.…”